Cas No.: | |
Chemical Name: | (S)-2-(N-((5S,11S,17S,18R)-5-((1H-imidazol-4-yl)methyl)-17-amino-6-(6-aminohexanoyl)-11-(3-guanidinopropyl)-18-hydroxy-12-(3-mercaptopropanoyl)-4,10,16-trioxo-3,6,9,12,15-pentaazanonadecyl)-5-guanidinopentanamido)heptanamide |
Synonyms: | DB-550;DB 550 |
SMILES: | C(N)(=O)[C@H](N(CCNC(=O)[C@@H](CC1=CNC=N1)N(C(=O)CCCCCN)CCNC(=O)[C@@H](CCCNC(N)=N)N(C(=O)CCS)CCNC(=O)[C@H](N)[C@@H](O)C)C(=O)CCCCNC(N)=N)CCCCC |
Formula: | C44H83N17O8S |
M.Wt: | 1010.319 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | DB550 (DB-550) is a potent, peptidomimetic of calcium-inducing domain (CID) that disrupts the CD95-PLCγ1 interaction without affecting the CD95-FADD interaction binds to SH3-PLCγ1 with Kd of 40.7 uM; abrogates the binding of PLCγ1 to CD95 in cells exposed to s-CD95L, inhibits the CD95-mediated Ca2+ response in a similar manner in Th17 cells to minCID and preventes Th17 trafficking across endothelial cells, does not affect the CD95-mediated apoptotic signaling pathway; abrogates the CD95-mediated Ca2+ response in mouse PBLs with IC50 of 68 nM, alleviates clinical symptoms in lupus-prone mice. |